Dobbs Ferry, NY, United States of America

Israel Lowy

USPTO Granted Patents = 31 (Patent Applications = 21)

CIPO Patents = 6 (Patent Applications = 17)

EPO Patents = 15 (Patent Applications = 29)

Average Co-Inventor Count = 3.4

ph-index = 8

Forward Citations = 230(Granted Patents)

Company Filing History:

18 out of 1,343

Regeneron Pharmaceuticals, Inc.

University of Massachusetts

patents

4. 2 out of 1,624

E. R. Squibb Sons, Inc.

patents

5. 1 out of 87

Inovio Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2008-2025

Loading Chart...

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12350318 - Combination therapy to treat brain cancer (2025-07-08),

2. 12054557 - Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer (2024-08-06),

3. 11926668 - Anti-PD-1 antibodies for treatment of lung cancer (2024-03-12),

4. 11919965 - Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies (2024-03-05),

5. 11590223 - Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies (2023-02-28),

6. 11505600 - Methods of treating skin cancer by administering a PD-1 inhibitor (2022-11-22),

7. 11439683 - Anti-angiogenic therapy of metastatic colorectal cancer (2022-09-13),

8. 11292842 - Anti-PD-1 antibodies for treatment of lung cancer (2022-04-05),

9. 10662244 - Methods for tumor treatment using CD3XCD20 bispecific antibody (2020-05-26),

10. 10626168 - B cell lineage based immunogen design with humanized animals (2020-04-21),

11. 10532096 - Methods and compositions comprising a combination of a VEGF antagonist and an anti-CTLA-4 antibody (2020-01-14),

12. 10525104 - Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer (2020-01-07),

13. 10457725 - Methods of treating skin cancer by administering a PD-1 inhibitor (2019-10-29),

14. 9968674 - Methods and compositions comprising a combination of a VEGF Trap and an anti-CTLA-4 antibody (2018-05-15),

15. 9963501 - B cell lineage based immunogen design with humanized animals (2018-05-08),

Title: Israel Lowy: Pioneering Innovations in Cancer Treatment

Introduction: Israel Lowy is a distinguished inventor based in Dobbs Ferry, NY, with an impressive portfolio of 30 patents. His innovative contributions primarily focus on developing novel therapeutic methods for various forms of cancer, showcasing his commitment to advancing medical science.

Latest Patents: Among his recent patents is a groundbreaking invention involving a combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer. This invention provides methods for treating, reducing the severity, or inhibiting the growth of B-cell cancers such as Hodgkin's lymphoma or acute lymphoblastic leukemia. The methods involve administering a therapeutically effective amount of an antibody that specifically binds to the programmed death 1 (PD-1) receptor in conjunction with a bispecific antibody targeting both CD20 and CD3. Additionally, Lowy has developed anti-PD-1 antibodies specifically for treating lung cancer, presenting methods that include administering a PD-1 antagonist to subjects whose cancer tissue exhibits PD-L1 expression.

Career Highlights: Israel Lowy has made significant strides in his career, contributing his expertise in cancer treatment at prominent companies such as Regeneron Pharmaceuticals, Inc. and Medarex Inc. His role in these organizations has been crucial in shaping innovative therapies that address critical healthcare challenges.

Collaborations: Throughout his career, Lowy has collaborated with esteemed colleagues in the field, including Gavin Thurston and Geoffrey M. Nichol. These partnerships have enhanced his research efforts and fostered the development of pioneering medical solutions.

Conclusion: Israel Lowy’s extensive body of work and innovative patents have positioned him as an influential figure in the realm of cancer treatment. His commitment to harnessing advanced therapeutic methods not only exemplifies his dedication to improving patient outcomes but also underscores the vital role inventors play in the advancement of healthcare technology.

This text is generated by artificial intelligence and may not be accurate.